RxDoctor Payments Data

Sanjeev Maniar, MD

Neurology · Fort Myers, FLNPI 1851352181

Payments from drug & device makers

$17,378in general payments, 2019–2025

Across 600 payments — averaging $28.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • AbbVie$1K
  • Novartis$1K
  • Sanofi$1K
  • EMD Serono, Inc.$986
  • Biogen$929
  • plus $10K from 52 others

What the payments were for

  • Speaking & faculty fees$420%
  • Travel & lodging$2,68215%
  • Food & beverage$14,54284%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott14$1,827
AbbVie(2 entities)70$1,268
Novartis75$1,264
Sanofi24$1,127
EMD Serono, Inc.22$986
Biogen42$929
Boston Scientific6$850
E.r. Squibb & Sons, L.L.C.11$817
Genentech USA, Inc.27$803
Amgen(2 entities)37$766
Acadia Pharmaceuticals Inc37$753
AstraZeneca(2 entities)22$715
Medtronic7$609
UCB, Inc.13$595
Teva Pharmaceuticals USA, Inc.15$350
GE HealthCare13$264
Bristol Myers Squibb10$214
Neurelis, Inc.12$194
Pfizer11$190
Tanabe Pharma America, Inc.5$170
Amneal Pharmaceuticals LLC3$166
Eisai Inc.7$156
Revance Therapeutics, Inc.2$149
Argenx US, Inc.6$146
Avanir Pharmaceuticals, Inc.12$144
Sunovion Pharmaceuticals Inc.9$137
Octapharma USA, Inc.7$131
Lundbeck LLC6$125
Lilly USA, LLC8$123
Corium, LLC5$123
Alnylam Pharmaceuticals Inc.5$112
Impel Pharmaceuticals Inc.1$110
TG Therapeutics, Inc.4$86
Biohaven Pharmaceutical Holding Company Ltd.4$82
SK Life Science, Inc.3$80
Johnson & Johnson(2 entities)4$79
Otsuka America Pharmaceutical, Inc.4$73
Kyowa Kirin, Inc.4$57
Takeda Pharmaceuticals U.S.A., Inc.2$53
Merz Pharmaceuticals, LLC2$50
Avion Pharmaceuticals3$48
Aucta Pharmaceuticals, Inc.2$44
Acorda Therapeutics, Inc3$42
Grifols USA, LLC2$38
Sanofi-aventis U.S. LLC2$37
Adamas Pharmaceuticals, Inc.2$37
Catalyst Pharmaceuticals, Inc.2$37
Upsher-smith Laboratories LLC2$36
Insightec,inc2$28
Springworks Therapeutics, Inc.1$25
Ipsen Biopharmaceuticals, Inc1$22
CSL Behring1$20
Sandoz1$19
Sumitomo Pharma America, Inc.1$17
Biohaven Pharmaceuticals, Inc.1$15
Zyla Life Sciences, Inc.1$15
Neurocrine Biosciences, Inc.1$12
Mallinckrodt Enterprises LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,378 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$1,151,028
Medicare patients
725
Services billed
30,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate40$275,957
Avonex (4 Pack)Interferon Beta-1a19$163,097
Teriflunomide31$108,252
NuplazidPimavanserin Tartrate15$67,253
Glatiramer Acetate17$46,387
UbrelvyUbrogepant30$30,981
QuliptaAtogepant27$28,733
Nurtec OdtRimegepant Sulfate17$24,921
Dalfampridine ErDalfampridine23$13,633
Aimovig AutoinjectorErenumab-Aooe15$12,721
Lacosamide35$4,628
Primidone106$4,523
Gabapentin348$4,419
Carbidopa-LevodopaCarbidopa/Levodopa164$3,541
Pregabalin129$3,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$350$275,95740 claims
BiogenAvonex (4 Pack)$929$163,09719 claims
Acadia Pharmaceuticals IncNuplazid$753$67,25315 claims
AbbVieUbrelvy, Qulipta$1,268$59,71357 claims
PfizerNurtec Odt$190$24,92117 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$166$1,31623 claims
Upsher-smith Laboratories LLCTopiramate$36$67057 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →